Scisparc Ltd (SPRC) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Scisparc Ltd (SPRC) has a cash flow conversion efficiency ratio of 22.975x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-1.86 Million) by net assets ($-81.00K). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Scisparc Ltd - Cash Flow Conversion Efficiency Trend (2006–2024)
This chart illustrates how Scisparc Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read SPRC total liabilities for a breakdown of total debt and financial obligations.
Scisparc Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Scisparc Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Kala Pharmaceuticals Inc
NASDAQ:KALA
|
-0.455x |
|
CME Group Bhd
KLSE:7018
|
0.059x |
|
Nobel29 Resources Corp
V:NBLC
|
0.055x |
|
Clean & Carbon Energy S.A.
WAR:CCE
|
-0.044x |
|
CLOCKCHAIN AG INH O.N.
F:U1DA
|
N/A |
|
Fon SE
WAR:FON
|
0.005x |
|
Scout Gaming Group AB
ST:SCOUT
|
-0.665x |
|
SpectraCure AB
ST:SPEC
|
-0.048x |
Annual Cash Flow Conversion Efficiency for Scisparc Ltd (2006–2024)
The table below shows the annual cash flow conversion efficiency of Scisparc Ltd from 2006 to 2024. For the full company profile with market capitalisation and key ratios, see Scisparc Ltd market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $8.94 Million | $-5.10 Million | -0.571x | +7.02% |
| 2023-12-31 | $9.59 Million | $-5.89 Million | -0.614x | +49.98% |
| 2022-12-31 | $6.45 Million | $-7.92 Million | -1.228x | -97.47% |
| 2021-12-31 | $8.14 Million | $-5.06 Million | -0.622x | +79.36% |
| 2020-12-31 | $1.43 Million | $-4.31 Million | -3.012x | +99.10% |
| 2019-12-31 | $14.00K | $-4.70 Million | -335.429x | -262.14% |
| 2018-12-31 | $77.00K | $-7.13 Million | -92.623x | -16869.15% |
| 2017-12-31 | $8.39 Million | $-4.58 Million | -0.546x | +78.87% |
| 2016-12-31 | $572.71K | $-1.48 Million | -2.583x | -125.51% |
| 2015-12-31 | $1.15 Million | $-1.32 Million | -1.145x | -107.05% |
| 2014-12-31 | $-116.33K | $-1.89 Million | 16.243x | +689.94% |
| 2013-12-31 | $995.26K | $-2.74 Million | -2.753x | +72.88% |
| 2012-12-31 | $389.43K | $-3.95 Million | -10.152x | -690.49% |
| 2011-12-31 | $2.95 Million | $-3.78 Million | -1.284x | -73.45% |
| 2010-12-31 | $5.09 Million | $-3.77 Million | -0.740x | -118.68% |
| 2009-12-31 | $5.64 Million | $-1.91 Million | -0.339x | +21.07% |
| 2008-12-31 | $7.52 Million | $-3.22 Million | -0.429x | -27.13% |
| 2007-12-31 | $9.41 Million | $-3.18 Million | -0.337x | -61.31% |
| 2006-12-31 | $6.98 Million | $-1.46 Million | -0.209x | -- |
About Scisparc Ltd
SciSparc Ltd., a clinical-stage pharmaceutical company, develops drugs based on cannabinoid therapies. Its drug development programs include SCI-110 for the treatment of Tourette syndrome and Alzheimer's disease and agitation; SCI-210 for the treatment of autism spectrum disorder and status epilepticus; and CannAmide, an anti-inflammatory and chronic pain solution. The company sells hemp seed oil… Read more